



Vivacta improves Point-of-Care Troponin Based Cardiac Tests

Sittingbourne, Kent, UK, 14 December 2011 - Vivacta Limited, the medical diagnostics company with a revolutionary system for point-of-care testing, announced today improved sensitivity in its panel of troponin-based cardiac tests.

Vivacta's technology platform can detect blood troponin at levels below 20pg/mL (picograms per millilitre).

Because an increase in troponin level from a very low initial level can suggest a heart attack, it is critical to have rapid sensitive tests which can result in earlier treatment to achieve better patient outcomes. It also provides clinicians with the basis for excluding a heart attack and so avoiding costly and unnecessary medical care. Troponin tests can also be used outside the emergency setting to determine risk of heart disease.

Dr Tim Carter, CEO of Vivacta said: "We are delighted to have achieved this challenging benchmark level for rapid detection of troponin. This is a key marker in cardiology, with enormous clinical significance and notoriously tricky to measure accurately, rapidly and in a point-of-care setting. We are confident that our platform can be applied to a full range of analytes requiring testing at the point-of-care."

-Ends-

About Vivacta

Vivacta Limited is applying its expertise in piezofilm technology to develop a range of new generation high performance Point-of-Care diagnostics able to deliver quantitative readings within 10 minutes from a single pin prick of blood. The Company's platform technology exploits the piezoelectric effect by which thermal perturbations on a piezofilm surface cause an electric charge to be produced. The measurement of this electric charge enables monitoring of chemical activity – or rate of binding between antibody and analyte – in an assay. In harnessing this piezofilm platform technology, Vivacta has developed PoC diagnostic products able to produce and present sensitive, precise and fully quantitative results, equivalent to those produced in laboratories. Each test requires only a finger prick sample, providing actionable results in 10 minutes or less. Rapid point-of-care testing avoids the delay caused by sending samples away to a remote laboratory for analysis and is essential where speed of diagnosis or frequent testing (monitoring) is medically necessary or economically desirable. Vivacta has generated an independent intellectual property position of over 10 patent families protecting the use of piezofilms in diagnostic assays. Vivacta's investors include Albion Ventures, HBM BioVentures, IDInvest (formerly AGF), Spark Ventures and Viking.

For more information please visit www.vivacta.com

Contacts:

Vivacta

Oliver Boucher

Tel: +44 1795 419400

ob@vivacta.com

College Hill

Nicole Yost/Gemma Howe

Tel: +44 (0) 207 866 7860

Gemma.howe@collegehill.com